Cas:320348-07-0 methyl 9-methylxanthene-9-carboxylate manufacturer & supplier

Chemical Name:methyl 9-methylxanthene-9-carboxylate

CAS.NO:320348-07-0

Synonyms:9H-Xanthene-9-carboxylic acid,9-methyl-,methyl ester;9-Methyl-xanthen-9-carbonsaeure-methylester;9-methyl-xanthene-9-carboxylic acid methyl ester;9-methyl-9H-xanthene-9-carboxylic acid methyl ester;methyl 9-methyl-9H-xanthene-9-carboxylate;methyl 9-methyl-xanthene-9-carboxylate

Molecular Formula:C₁₆H₁₄O₃

Molecular Weight:254.28100

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:35.53000

Exact Mass:254.09400

LogP:3.27130

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 9H-Xanthene-9-carboxylic acid,9-methyl-,methyl ester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,methyl 9-methyl-xanthene-9-carboxylate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,9H-Xanthene-9-carboxylic acid,9-methyl-,methyl ester Use and application,9-methyl-xanthene-9-carboxylic acid methyl ester technical grade,usp/ep/jp grade.

Related News: Australia has started denying entry to all travelers who have come from or transited through mainland China. methyl 9-methylxanthene-9-carboxylate manufacturer Australia has started denying entry to all travelers who have come from or transited through mainland China. methyl 9-methylxanthene-9-carboxylate supplier Featured APIs: Production capacity continues to expand, targeted patents expire. Original research drugs: industry entry barriers are high, performance stability and certainty are high. methyl 9-methylxanthene-9-carboxylate vendor The drug substance is an active product that has completed the synthetic route, and the intermediate is a product in one place in the synthetic route. methyl 9-methylxanthene-9-carboxylate factory Featured APIs: Production capacity continues to expand, targeted patents expire. Original research drugs: industry entry barriers are high, performance stability and certainty are high.